258 related articles for article (PubMed ID: 31416841)
21. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
22.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
23. Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop.
Wang J; Lu Q; Cai J; Wang Y; Lai X; Qiu Y; Huang Y; Ke Q; Zhang Y; Guan Y; Wu H; Wang Y; Liu X; Shi Y; Zhang K; Wang M; Peng Xiang A
Nat Commun; 2019 Nov; 10(1):5043. PubMed ID: 31695040
[TBL] [Abstract][Full Text] [Related]
24. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
Best SA; De Souza DP; Kersbergen A; Policheni AN; Dayalan S; Tull D; Rathi V; Gray DH; Ritchie ME; McConville MJ; Sutherland KD
Cell Metab; 2018 Apr; 27(4):935-943.e4. PubMed ID: 29526543
[TBL] [Abstract][Full Text] [Related]
25. A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer.
Jiang C; Ward NP; Prieto-Farigua N; Kang YP; Thalakola A; Teng M; DeNicola GM
Redox Biol; 2022 Aug; 54():102358. PubMed ID: 35667246
[TBL] [Abstract][Full Text] [Related]
26. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
Wang Q; Ma J; Lu Y; Zhang S; Huang J; Chen J; Bei JX; Yang K; Wu G; Huang K; Chen J; Xu S
Oncogene; 2017 Sep; 36(37):5321-5330. PubMed ID: 28534518
[TBL] [Abstract][Full Text] [Related]
27. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670
[TBL] [Abstract][Full Text] [Related]
28. NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer.
Weiss-Sadan T; Ge M; Hayashi M; Gohar M; Yao CH; de Groot A; Harry S; Carlin A; Fischer H; Shi L; Wei TY; Adelmann CH; Wolf K; Vornbäumen T; Dürr BR; Takahashi M; Richter M; Zhang J; Yang TY; Vijay V; Fisher DE; Hata AN; Haigis MC; Mostoslavsky R; Bardeesy N; Papagiannakopoulos T; Bar-Peled L
Cell Metab; 2023 Mar; 35(3):487-503.e7. PubMed ID: 36841242
[TBL] [Abstract][Full Text] [Related]
29. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
30. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
Mahaffey CM; Mahaffey NC; Holland W; Zhang H; Gandara DR; Mack PC; Forman HJ
J Thorac Oncol; 2012 Jan; 7(1):34-9. PubMed ID: 22089114
[TBL] [Abstract][Full Text] [Related]
31. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.
Hast BE; Goldfarb D; Mulvaney KM; Hast MA; Siesser PF; Yan F; Hayes DN; Major MB
Cancer Res; 2013 Apr; 73(7):2199-210. PubMed ID: 23382044
[TBL] [Abstract][Full Text] [Related]
32. Emerging roles of Nrf2 signal in non-small cell lung cancer.
Tian Y; Liu Q; He X; Yuan X; Chen Y; Chu Q; Wu K
J Hematol Oncol; 2016 Feb; 9():14. PubMed ID: 26922479
[TBL] [Abstract][Full Text] [Related]
33. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
[TBL] [Abstract][Full Text] [Related]
34. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Zhang B; Ma Z; Tan B; Lin N
Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
[TBL] [Abstract][Full Text] [Related]
35. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
36. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Singh A; Daemen A; Nickles D; Jeon SM; Foreman O; Sudini K; Gnad F; Lajoie S; Gour N; Mitzner W; Chatterjee S; Choi EJ; Ravishankar B; Rappaport A; Patil N; McCleland M; Johnson L; Acquaah-Mensah G; Gabrielson E; Biswal S; Hatzivassiliou G
Clin Cancer Res; 2021 Feb; 27(3):877-888. PubMed ID: 33077574
[TBL] [Abstract][Full Text] [Related]
37. Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis.
Vartanian S; Ma TP; Lee J; Haverty PM; Kirkpatrick DS; Yu K; Stokoe D
Mol Cell Proteomics; 2016 Apr; 15(4):1220-31. PubMed ID: 26711467
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells.
Deen AJ; Adinolfi S; Härkönen J; Patinen T; Liu X; Laitinen T; Takabe P; Kainulainen K; Pasonen-Seppänen S; Gawriyski LM; Arasu UT; Selvarajan I; Mäkinen P; Laitinen H; Kansanen E; Kaikkonen MU; Poso A; Varjosalo M; Levonen AL
Redox Biol; 2024 Feb; 69():103031. PubMed ID: 38184997
[TBL] [Abstract][Full Text] [Related]
39. Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
Saigusa D; Motoike IN; Saito S; Zorzi M; Aoki Y; Kitamura H; Suzuki M; Katsuoka F; Ishii H; Kinoshita K; Motohashi H; Yamamoto M
Cancer Sci; 2020 Feb; 111(2):667-678. PubMed ID: 31828882
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma.
Hamada S; Shimosegawa T; Taguchi K; Nabeshima T; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G65-G74. PubMed ID: 28971839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
